Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans - PubMed (original) (raw)
Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans
D C Lefroy et al. Circulation. 1993 Jul.
Abstract
Background: NG-Monomethyl-L-arginine (L-NMMA), a specific inhibitor of nitric oxide synthesis, was used to determine the effects of inhibition of nitric oxide synthesis in the human coronary circulation.
Methods and results: Twelve patients (mean age, 52 +/- 2 years) with normal epicardial coronary arteries were studied. The surface ECG, systemic blood pressure, and coronary venous oxygen saturation (coronary SvO2), an index of coronary blood flow, were monitored continuously. Coronary artery diameter was measured by quantitative arteriography. L-NMMA was given as intracoronary infusions at 2 mL/min via the diagnostic arteriography catheter. In two patients, low doses (0.01 to 5 mumol/min) of L-NMMA were infused into the nondominant right coronary artery. There was no evidence of ischemia in these patients, who were not included in the final analysis. In 10 patients, higher doses of L-NMMA (4, 10, and 25 mumol/min, each for 5 minutes) were infused into the left coronary artery. In six patients, incremental doses of acetylcholine were infused (1, 10, and 100 nmol/min, each for 3 minutes) before and after the L-NMMA infusion. Finally, in all patients, sodium nitroprusside, a nitric oxide donor, was infused. No patient developed myocardial ischemia. The heart rate and systemic blood pressure remained unchanged throughout the infusions. L-NMMA (25 mumol/min), compared with the control saline infusion, caused a significant reduction in distal (-5.9 +/- 2.1%, P = 0.021) but not proximal left anterior descending coronary artery (LAD) diameter and a fall in coronary SvO2 from 37.5 +/- 2.8% to 34.3 +/- 2.8% (P = 0.019). Sodium nitroprusside dilated the proximal (17.8 +/- 6.9%, P = 0.033) and distal (24.5 +/- 6.5%, P = 0.006) LAD and increased the coronary SvO2 to 61.6 +/- 5.0% (P = 0.0002). Acetylcholine caused significant dilatation of the distal (13.8 +/- 5.4%, P = 0.049) but not proximal LAD and a significant increase in coronary SvO2 from 36.5 +/- 3.5% to 59.2 +/- 2.8% (P < 0.0001). After L-NMMA, acetylcholine-induced dilatation of the distal LAD was abolished, but the rise in coronary SvO2 was unchanged.
Conclusions: Inhibition of nitric oxide synthesis in the human coronary circulation caused a decrease in basal distal LAD diameter and basal coronary blood flow assessed by coronary SvO2, indicating that there is a small basal release of nitric oxide in the distal epicardial coronary arteries and resistive vessels. Distal epicardial coronary artery dilatation in response to acetylcholine is nitric oxide dependent, but coronary resistive vessel dilatation is not.
Comment in
- Endothelium-dependent vasoregulation of coronary artery diameter and blood flow.
Vogel RA. Vogel RA. Circulation. 1993 Jul;88(1):325-7. doi: 10.1161/01.cir.88.1.325. Circulation. 1993. PMID: 8319348 No abstract available.
Similar articles
- Flow-mediated vasodilation of human epicardial coronary arteries: effect of inhibition of nitric oxide synthesis.
Shiode N, Morishima N, Nakayama K, Yamagata T, Matsuura H, Kajiyama G. Shiode N, et al. J Am Coll Cardiol. 1996 Feb;27(2):304-10. doi: 10.1016/0735-1097(95)00465-3. J Am Coll Cardiol. 1996. PMID: 8557898 - Contribution of nitric oxide to metabolic coronary vasodilation in the human heart.
Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO 3rd. Quyyumi AA, et al. Circulation. 1995 Aug 1;92(3):320-6. doi: 10.1161/01.cir.92.3.320. Circulation. 1995. PMID: 7634444 Clinical Trial. - Importance of nitric oxide in the coronary artery at rest and during pacing in humans.
Nishikawa Y, Ogawa S. Nishikawa Y, et al. J Am Coll Cardiol. 1997 Jan;29(1):85-92. doi: 10.1016/s0735-1097(96)00429-9. J Am Coll Cardiol. 1997. PMID: 8996299 - Modulation of coronary autoregulatory responses by endothelium-derived nitric oxide.
Canty JM Jr, Smith TP Jr. Canty JM Jr, et al. Int J Cardiol. 1995 Jul;50(3):207-15. doi: 10.1016/0167-5273(95)02379-b. Int J Cardiol. 1995. PMID: 8537143 Review.
Cited by
- Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction.
Anderson TJ. Anderson TJ. Heart Fail Rev. 2003 Jan;8(1):71-86. doi: 10.1023/a:1022199021949. Heart Fail Rev. 2003. PMID: 12652161 Review. - A dose-response study of nitric oxide synthase inhibition in different vascular beds in man.
Hjorth Lassen L, Klingenberg Iversen H, Olesen J. Hjorth Lassen L, et al. Eur J Clin Pharmacol. 2003 Oct;59(7):499-505. doi: 10.1007/s00228-003-0662-7. Epub 2003 Sep 6. Eur J Clin Pharmacol. 2003. PMID: 13680036 Clinical Trial. - Role for endothelium-derived hyperpolarizing factor in vascular tone in rat mesenteric and hindlimb circulations in vivo.
Parkington HC, Chow JA, Evans RG, Coleman HA, Tare M. Parkington HC, et al. J Physiol. 2002 Aug 1;542(Pt 3):929-37. doi: 10.1113/jphysiol.2002.021030. J Physiol. 2002. PMID: 12154190 Free PMC article. - L-Arginine-Nitric Oxide-Asymmetric Dimethylarginine Pathway and the Coronary Circulation: Translation of Basic Science Results to Clinical Practice.
Cziráki A, Lenkey Z, Sulyok E, Szokodi I, Koller A. Cziráki A, et al. Front Pharmacol. 2020 Sep 29;11:569914. doi: 10.3389/fphar.2020.569914. eCollection 2020. Front Pharmacol. 2020. PMID: 33117166 Free PMC article. Review. - Impaired vascular sensitivity to nitric oxide in the coronary microvasculature after endotoxaemia.
Bogle RG, McLean PG, Ahluwalia A, Vallance P. Bogle RG, et al. Br J Pharmacol. 2000 May;130(1):118-24. doi: 10.1038/sj.bjp.0703267. Br J Pharmacol. 2000. PMID: 10781006 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources